• A simple blood test that can diagnose and predict whether a patient will develop diabetic kidney disease before clinical symptoms appear.
  • In clinical studies, PromarkerD predicted 86% of previously disease-free patients who went on to develop diabetic kidney disease within four years.
  • Diagnosing diabetic kidney disease early allows the patient to take steps to protect their kidneys from further damage.

For more information on PromarkerD, please visit


The need for PromarkerD

*  Diabetes prevalence information in the video is based on the IDF Diabetes Atlas, 6th edition 2014. The IDF Diabetes Atlas, 7th edition 2015 estimated that 415 million people worldwide, or 1 in 11 people, had diabetes in 2015.


To develop PromarkerD, Proteomics International used the Promarker™ platform to identifiy a panel of novel protein markers (biomarkers) that are significantly effective in diagnosing and predicting diabetic kidney disease. The PromarkerD test measures the concentration of these biomarkers to diagnose and predict a person’s risk of developing diabetic kidney disease.

The ability of the biomarkers to diagnose and predict diabetic kidney disease was studied and verified in three clinical studies. The results of these studies have been published and presented at the American Diabetes Association’s 77th Annual Scientific Sessions (ADA).


  • This field is for validation purposes and should be left unchanged.